The only accurate crypto trading system I know …

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

Douglas Hughes Biography and Net Worth

Director of Immunovant

Doug Hughes has served as a member of our board of directors since September 2020. Since 2019, Mr. Hughes has served as Chief Financial Officer of Calyxo Inc., a urology medical device company. From 2011 until 2018, Mr. Hughes was Chief Financial Officer of NeoTract, Inc., a urology company. He served as Chief Financial Officer and Chief Operating Officer for Nellix, Inc., an endovascular graft company from 2010 until 2011. Before joining Nellix, Inc., Mr. Hughes served as Chief Financial officer for Evalve Inc., a cardiovascular company, from 2009 until 2010. Prior to 2009, Mr. Hughes held a variety of senior finance management positions at Boston Scientific, Guidant Corporation and The Clorox Company. Mr. Hughes is currently a member of the board of directors of Immunovant, Inc., a publicly-held biopharmaceutical company. Mr. Hughes received a B.S. in Finance from San Francisco State University and an M.B.A. from University of Chicago.

How do I contact Douglas J. Hughes?: The corporate mailing address for Mr. Hughes and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Douglas J. Hughes' contact information.
Has Douglas J. Hughes been buying or selling shares of Immunovant?: Douglas J. Hughes has not been actively trading shares of Immunovant during the past quarter. Most recently, on Friday, August 27th, Douglas J. Hughes bought 18,247 shares of Immunovant stock. The stock was acquired at an average cost of $8.24 per share, with a total value of $150,355.28. Learn More on Douglas J. Hughes' trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, Immunovant insiders bought shares 1 times. They purchased a total of 1,526,316 shares worth more than $58,000,008.00. During the last twelve months, insiders at the sold shares 32 times. They sold a total of 422,975 shares worth more than $10,417,957.68. The most recent insider tranaction occured on April, 17th when CFO Eva Renee Barnett sold 12,253 shares worth more than $356,072.18. Insiders at Immunovant own 4.8% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 4/17/2024.

Douglas J. Hughes Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/27/2021	Buy	18,247	$8.24	$150,355.28

Douglas J. Hughes Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $28.80

$28.40

$29.54

50 Day Range

MA: $32.50

$28.22

$38.36

2 Week Range

Now: $28.80

$15.90

$45.58

Volume

667,914 shs

Average Volume

1,012,856 shs

Market Capitalization

$4.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.65